Association of cytotoxic effector memory CD8 T cells with sustained unresponsiveness after peanut oral immunotherapy.
作者信息
Seastedt Hana, Han Xiaorui, Fernandes Andrea, Galli Stephen J, Boyd Scott D, Nadeau Kari C, Manohar Monali, Chinthrajah Sharon
机构信息
Department of Medicine, Sean N. Parker Center for Allergy and Asthma Research, Stanford University School of Medicine, Stanford, California, USA.
Department of Microbiology and Immunology, Stanford University School of Medicine, Stanford, California, USA.
出版信息
Allergy. 2025 Jan;80(1):319-322. doi: 10.1111/all.16307. Epub 2024 Sep 7.
Abstract
摘要
相似文献
1
Association of cytotoxic effector memory CD8 T cells with sustained unresponsiveness after peanut oral immunotherapy.花生口服免疫治疗后细胞毒性效应记忆CD8 T细胞与持续无反应性的关联
Allergy. 2025 Jan;80(1):319-322. doi: 10.1111/all.16307. Epub 2024 Sep 7.
2
Administration of a probiotic with peanut oral immunotherapy: A randomized trial.口服花生免疫治疗联合益生菌治疗：一项随机试验。
J Allergy Clin Immunol. 2015 Mar;135(3):737-44.e8. doi: 10.1016/j.jaci.2014.11.034. Epub 2015 Jan 13.
3
Sustained unresponsiveness to peanut in subjects who have completed peanut oral immunotherapy.完成花生口服免疫治疗的患者对花生持续无反应。
J Allergy Clin Immunol. 2014 Feb;133(2):468-75. doi: 10.1016/j.jaci.2013.11.007. Epub 2013 Dec 19.
4
Probiotic peanut oral immunotherapy versus oral immunotherapy and placebo in children with peanut allergy in Australia (PPOIT-003): a multicentre, randomised, phase 2b trial.益生菌花生口服免疫治疗与口服免疫治疗和安慰剂在澳大利亚花生过敏儿童中的比较（PPOIT-003）：一项多中心、随机、2b 期试验。
Lancet Child Adolesc Health. 2022 Mar;6(3):171-184. doi: 10.1016/S2352-4642(22)00006-2. Epub 2022 Feb 4.
5
Peanut Oral Immunotherapy: State of the Art.花生口服免疫治疗：最新进展。
Immunol Allergy Clin North Am. 2020 Feb;40(1):97-110. doi: 10.1016/j.iac.2019.09.005. Epub 2019 Nov 6.
6
Baseline epitope-specific IgE profiles are predictive of sustained unresponsiveness or high threshold 1-year post oral immunotherapy in the POISED trial.在POISED试验中，基线表位特异性IgE谱可预测口服免疫疗法后1年的持续无反应性或高阈值。
J Allergy Clin Immunol. 2025 Mar;155(3):923-931.e2. doi: 10.1016/j.jaci.2024.10.017. Epub 2024 Nov 5.
7
CD8 T cell differentiation status correlates with the feasibility of sustained unresponsiveness following oral immunotherapy.CD8 T 细胞分化状态与口服免疫治疗后持续无反应的可行性相关。
Nat Commun. 2022 Nov 4;13(1):6646. doi: 10.1038/s41467-022-34222-8.
8
Optimal period for achieving sustained unresponsiveness in peanut oral immunotherapy.花生口服免疫疗法中实现持续无反应的最佳时期。
Asia Pac Allergy. 2023 Sep;13(3):97-104. doi: 10.5415/apallergy.0000000000000110. Epub 2023 Sep 7.
9
Probiotic peanut oral immunotherapy is associated with long-term persistence of 8-week sustained unresponsiveness and long-lasting quality-of-life improvement.益生菌花生口服免疫疗法与8周持续无反应的长期持续存在以及生活质量的长期改善相关。
Clin Exp Allergy. 2022 Jun;52(6):806-811. doi: 10.1111/cea.14137. Epub 2022 May 10.
10
Remission of peanut allergy is associated with rewiring of allergen-driven T helper 2-related gene networks.花生过敏的缓解与过敏原驱动的辅助性 T 细胞 2 相关基因网络的重布线有关。
Allergy. 2022 Oct;77(10):3015-3027. doi: 10.1111/all.15324. Epub 2022 May 25.
本文引用的文献
1
Targeting type 2 immunity and the future of food allergy treatment.靶向 2 型免疫与食物过敏治疗的未来。
J Exp Med. 2023 Apr 3;220(4). doi: 10.1084/jem.20221104. Epub 2023 Mar 3.
2
CD8 T cell differentiation status correlates with the feasibility of sustained unresponsiveness following oral immunotherapy.CD8 T 细胞分化状态与口服免疫治疗后持续无反应的可行性相关。
Nat Commun. 2022 Nov 4;13(1):6646. doi: 10.1038/s41467-022-34222-8.
3
Sustained outcomes in oral immunotherapy for peanut allergy (POISED study): a large, randomised, double-blind, placebo-controlled, phase 2 study.口服免疫治疗花生过敏的持续疗效（POISED 研究）：一项大型、随机、双盲、安慰剂对照、2 期研究。
Lancet. 2019 Oct 19;394(10207):1437-1449. doi: 10.1016/S0140-6736(19)31793-3. Epub 2019 Sep 12.
4
Sustained unresponsiveness in peanut oral immunotherapy.花生口服免疫疗法中的持续无反应性。
Lancet. 2019 Oct 19;394(10207):1392-1393. doi: 10.1016/S0140-6736(19)31816-1. Epub 2019 Sep 12.
5
Oral immunotherapy for treatment of egg allergy in children.儿童蛋过敏的口服免疫治疗。
N Engl J Med. 2012 Jul 19;367(3):233-43. doi: 10.1056/NEJMoa1200435.
Zotero 插件